+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

C

Actively Recruiting

This trial investigates treatments for adults with relapsed or refractory multiple myeloma who have already received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. Researchers are comparing the effects of a new drug called JNJ-79635322 with an anti-BCMAxCD3 bispecific antibody called teclistamab. The goal is to evaluate how well JNJ-79635322 works in comparison to the existing antibody treatment. Participants will be randomly assigned to receive either JNJ-79635322 or teclistamab, both given as subcutaneous injections. Treatments will continue until the disease progresses or participants experience intolerable side effects. The study is designed as a phase 3 trial, with treatment lasting potentially up to several years depending on individual response and tolerance. During the trial, participants will have regular assessments to monitor response to treatment, disease progression, side effects, and quality of life. Measures include overall response, progression-free survival, complete response rates, symptom and functioning questionnaires, and laboratory tests. Safety is closely monitored, along with drug levels and immune responses. The total participation period may last up to five years and seven months, with ongoing evaluations throughout this time.

Age: 18Years +All GendersPhase 3
157 locations
E

Actively Recruiting

Researchers are evaluating the use of mirikizumab in children and adolescents aged 2 to 17 years with moderately to severely active Crohns disease. The study aims to assess the drugs effectiveness, safety, tolerability, and how well it is absorbed in the body. This phase 3 clinical trial involves participants with confirmed Crohns disease or fistulizing Crohns disease who have shown an inadequate response or intolerance to at least one prior medication. Participants will receive mirikizumab intravenously or subcutaneously, with dosing based on their weight category. The study includes a 12-week induction period, followed by a maintenance phase lasting from week 12 to week 52. After the treatment periods, there is a safety follow-up period lasting up to 16 weeks. Overall, the study will last approximately 74 weeks and may involve up to 19 visits. Throughout the study, participants will undergo various assessments including clinical response evaluations using the Pediatric Crohns Disease Activity Index PCDAI and endoscopic scoring. Researchers will monitor changes in inflammatory markers such as C-reactive protein and fecal calprotectin, as well as pharmacokinetic measures of mirikizumab. Safety and tolerability will be tracked during the follow-up period, with all evaluations scheduled at multiple timepoints throughout the study.

Age: 2Years - 17YearsAll GendersPhase 3
81 locations
R

Actively Recruiting

Researchers are observing how men with metastatic hormone-sensitive prostate cancer mHSPC respond to treatment with darolutamide combined with androgen deprivation therapy ADT, with or without the chemotherapy drug docetaxel. This international, open-label, multi-cohort study aims to understand the real-world effectiveness and safety of these treatments in routine medical practice. The study will enroll about 1,600 male patients primarily from Europe, focusing on those already decided to receive darolutamide before joining the study. Participants will be divided into two groups one receiving darolutamide plus ADT and docetaxel triplet therapy, and the other receiving darolutamide plus ADT without docetaxel doublet therapy. Treatment is given according to local standard care and chosen by the treating physician. No additional study-specific treatments or procedures are required, as data is collected during routine care visits over the study period. During the study, researchers will collect data on prostate-specific antigen PSA levels, survival rates, time to new treatments, progression of disease, adverse events, quality of life, and other clinical information. Data collection is done via electronic records during regular doctor visits with no extra tests beyond standard care. The study will last up to four years with periodic analyses to help improve understanding of darolutamide use in everyday clinical settings.

Age: 18Years +MALE
16 locations